Vascular Biology and Atherosclerosis Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Trends Cardiovasc Med. 2012 Feb;22(2):48-53. doi: 10.1016/j.tcm.2012.06.011. Epub 2012 Jul 28.
Atherosclerosis initiated by hyperlipidemia is modulated by immune cells in its development, progression, and rupture that results in thrombotic arterial occlusion leading to strokes and myocardial infarction. B cells initially thought to be atheroprotective provide opposing roles by their different subsets. Unlike B2 cells that are atherogenic, serosal B1a cells are atheroprotective by producing natural IgM antibodies that clear modified low-density lipoprotein and apoptotic and necrotic debris. In addition to natural IgM antibodies, B1a cells may act as regulatory B cells by producing the anti-inflammatory cytokine interleukin-10, which inhibits proinflammatory cytokines secreted by activated macrophages and T cells in atherosclerotic lesions. These findings suggest in vivo expansion of atheroprotective B1a cells as a potential therapeutic strategy to augment the benefits of lipid-lowering statin therapy.
由高血脂引起的动脉粥样硬化在其发展、进展和破裂过程中受到免疫细胞的调节，导致血栓性动脉闭塞，从而导致中风和心肌梗死。最初被认为具有抗动脉粥样硬化作用的 B 细胞通过其不同亚群提供相反的作用。与促动脉粥样硬化的 B2 细胞不同，浆膜 B1a 细胞通过产生清除修饰的低密度脂蛋白和凋亡及坏死碎片的天然 IgM 抗体而具有抗动脉粥样硬化作用。除了天然 IgM 抗体外，B1a 细胞还可以通过产生抗炎细胞因子白细胞介素-10 作为调节性 B 细胞发挥作用，抑制动脉粥样硬化病变中活化的巨噬细胞和 T 细胞分泌的促炎细胞因子。这些发现表明，体内扩增保护性 B1a 细胞作为一种潜在的治疗策略，可能会增加降脂他汀类药物治疗的益处。
